Compounders Research Compare

NeuroSense Therapeutics Ltd.(NRSN)

Biotechnology · Herzliya, TA

$3.95-0.08 (-1.99%)

Delayed quote: Oct 6, 2026, 11:58 AM EDT

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Herzliya, TA

17 employees

www.neurosense-tx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Alon Ben-Noon

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T16:04:18.277Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:04:18.277Z.

Quote observation: 2026-10-06T15:58:41.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 6,981,589
Total debt · period ending 2025-12-31: 170,000
Cash · period ending 2025-12-31: 166,000
TTM free cash flow · period ending 2025-12-31: N/A

FMP input reference: 7269c43ec051f04bc9b25698fa87f96476c1bd81d443a59abbb4ab2a9593cf8e

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NRSN EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

NRSN Competitors' EV/FCF Ratio

NeuroSense Therapeutics Ltd.

Current

Market Cap

$6.98M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mangoceuticals, Inc.

Market Cap

$6.98M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bolt Biotherapeutics, Inc.

Market Cap

$6.99M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA BIO, Inc.

Market Cap

$7.16M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curanex Pharmaceuticals Inc Common Stock

Market Cap

$7.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InMed Pharmaceuticals Inc.

Market Cap

$7.25M

EV/FCF Ratio

N/A

TTM Avg

41004.37x

3Y Avg

41004.37x

5Y Avg

41004.37x

Co-Diagnostics, Inc.

Market Cap

$6.69M

EV/FCF Ratio

N/A

TTM Avg

1.99x

3Y Avg

10.75x

5Y Avg

10.75x

Longeveron Inc.

Market Cap

$7.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNS Pharmaceuticals, Inc.

Market Cap

$7.29M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclarion, Inc.

Market Cap

$6.66M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
NeuroSense Therapeutics Ltd. (NRSN)	$6.98M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$6.98M	N/A	N/A	N/A	N/A
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.99M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.16M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.23M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.25M	N/A	41004.37x	41004.37x	41004.37x
Co-Diagnostics, Inc. (CODX)vs ›	$6.69M	N/A	1.99x	10.75x	10.75x
Longeveron Inc. (LGVN)vs ›	$7.27M	N/A	N/A	N/A	N/A
CNS Pharmaceuticals, Inc. (CNSP)vs ›	$7.29M	N/A	N/A	N/A	N/A
Aclarion, Inc. (ACON)vs ›	$6.66M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics